<DOC>
	<DOC>NCT01488162</DOC>
	<brief_summary>This multi-center, prospective, observational study will describe the management of relapsing or refractory chronic lymphocytic leukemia (CLL) patients. Data will be collected for 2 years.</brief_summary>
	<brief_title>An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL) with first or second relapse Previous treatment with MabThera/Rituxan MabThera/Rituxan treatment planned for current relapse Richter syndrome Life expectancy &lt;6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>